Abstract
Introduction: The UK government introduced the two-week rule (TWR) to improve the diagnosis and treatment of gastrointestinal (GI) cancers. This updated review systematically identifies new articles since 2009 and presents an overview of the previous and new findings combined for both upper GI cancer (UGCs) and colorectal cancers (CRCs).
Methods: We analysed all peer-reviewed articles and conference abstracts with GI cancer detection rates following TWR referral and/or the proportion of TWR-referred GI cancers from the total number diagnosed during the study period. We reported average cancer detection rates and split the data according to four time periods to determine whether TWR effectiveness improved over time.
Results: The average cancer detection rate by the TWR for all studies was 11.6% for CRC and 8.3% for UGC. We found a decrease in cancer detection rates over time for CRC from 14.4% in 2000-2002 to 7.2% in 2009-2012. However, UGC detection rates increased over time from 8.5% in 2000-2002 to 11.4% in 2005-2008. We found that on average, 30.8% of CRCs and 28.8% of UGCs were detected following referrals using the TWR system and that these proportions had increased over time from 30.6% to 38.4% for CRC and from 26.8% to 52% for UGC.
Conclusion: The TWR is not still sufficiently effective in diagnosing GI cancers in patients, suggesting that the referral guidelines need to be improved. Our findings do suggest that the TWR is being used more frequently than alternative routes.
Keywords: Gastrointestinal cancer, two-week referral, fast-track, cancer detection rate.
Current Cancer Therapy Reviews
Title:Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review
Volume: 10 Issue: 1
Author(s): Kymberley Thorne, Hayley A. Hutchings and Glyn Elwyn
Affiliation:
Keywords: Gastrointestinal cancer, two-week referral, fast-track, cancer detection rate.
Abstract: Introduction: The UK government introduced the two-week rule (TWR) to improve the diagnosis and treatment of gastrointestinal (GI) cancers. This updated review systematically identifies new articles since 2009 and presents an overview of the previous and new findings combined for both upper GI cancer (UGCs) and colorectal cancers (CRCs).
Methods: We analysed all peer-reviewed articles and conference abstracts with GI cancer detection rates following TWR referral and/or the proportion of TWR-referred GI cancers from the total number diagnosed during the study period. We reported average cancer detection rates and split the data according to four time periods to determine whether TWR effectiveness improved over time.
Results: The average cancer detection rate by the TWR for all studies was 11.6% for CRC and 8.3% for UGC. We found a decrease in cancer detection rates over time for CRC from 14.4% in 2000-2002 to 7.2% in 2009-2012. However, UGC detection rates increased over time from 8.5% in 2000-2002 to 11.4% in 2005-2008. We found that on average, 30.8% of CRCs and 28.8% of UGCs were detected following referrals using the TWR system and that these proportions had increased over time from 30.6% to 38.4% for CRC and from 26.8% to 52% for UGC.
Conclusion: The TWR is not still sufficiently effective in diagnosing GI cancers in patients, suggesting that the referral guidelines need to be improved. Our findings do suggest that the TWR is being used more frequently than alternative routes.
Export Options
About this article
Cite this article as:
Thorne Kymberley, Hutchings A. Hayley and Elwyn Glyn, Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152459
DOI https://dx.doi.org/10.2174/157339471001140815152459 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Characterization of Solid Lipid Nanoparticles Containing Caffeic Acid and Determination of its Effects on MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review
Recent Advances in Drug Delivery and Formulation Evaluation of the Diagnostic Properties of Serum hsa-miR-223-5p in the Detection of Gastric Cancer: A Case-Control Study
Anti-Cancer Agents in Medicinal Chemistry Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Development of Schiff bases from Amikacin: Synthesis, Antibacterial, Anti-urease Activities and Molecular Docking Studies
Letters in Drug Design & Discovery Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies The Use of Interferon-Gamma Therapy in Chronic Granulomatous Disease
Recent Patents on Anti-Infective Drug Discovery Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Phytochemical Investigation and Antimutagenic Potential of Ethanolic Extracts of Emblica officinalis, Terminalia chebula and Terminalia bellirica
The Natural Products Journal